A new tamper-resistant formulation of controlled-release oxycodone was not found to reduce opioid use or harm at the population level.
The FDA has tentatively approved an update to the Arymo ER extended-release tablets labeling to include data from an intranasal abuse-deterrent claim.
Multiple new drugs for pain management have been recently introduced or approved, and additional agents are currently under investigation.
Administration of abuse-deterrent formulations of immediate-release oxycodone and extended-release morphine leads to slower and lower absorption rates in nondependent recreational drug users compared with standard oxycodone and morphine formulations.
Egalet announced the launch of Arymo ER extended-release tablets for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
There is a lot of opportunity to improve on what can be offered to patients.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- To Improve Healthcare Policy, Congress Needs More Physicians
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- The Ethical Argument Against Publishing Medical Research: What Responsibility Do Journal Editors Have?
- Poll: Should Migraineurs Avoid Headache Triggers?